NCT06473961

A Phase Ib Study of GC101 in NSCLC

An Open, Single-armed, Phase Ib Study to Evaluate the Safety and Efficacy Using Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) in Patients With Non-Small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Shanghai Juncell Therapeutics · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 36 months.

Conditions

• Non Small Cell Lung Cancer Metastatic
• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Autologous Tumor Infiltrating Lymphocytes	A tumor sample is resected from each participant and cultured ex vivo to generate tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC101 TIL followed low-dose PD-1 antibody.

Timeline

• Start date: 2024-10-14
• Primary completion: 2026-01-01
• Completion: 2027-07-01
• First posted: 2024-06-25
• Last updated: 2025-12-11

Locations

1 site across 1 country: China